论文部分内容阅读
目的研究分析老年急性心肌梗死患者经皮冠状动脉介入治疗(PCI)的临床效果。方法急性心肌梗死老年患者224例,随机分为对照组和观察组,各112例。对照组患者采用溶栓治疗,观察组患者应用经皮冠状动脉介入治疗,观察对比两组患者临床效果。结果治疗后,对照组患者中显效43例,有效47例,无效22例;观察组患者中显效63例,有效42例,无效7例;对照组治疗总有效率为80.4%,低于观察组的93.8%,比较差异具有统计学意义(P<0.05)。治疗期间,观察组患者的不良反应发生率为6.3%,其中1例过敏、3例出血、3例室性心律失常;对照组患者的不良反应发生率为17.9%,其中过敏5例、出血6例,室性心律失常9例;观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论在老年急性心肌梗死患者的治疗中,相对于常规的静脉溶栓治疗措施,患者经皮冠状动脉介入治疗临床效果更显著,且还可减少治疗期间不良反应的产生,具有推广价值。
Objective To study the clinical effect of percutaneous coronary intervention (PCI) in elderly patients with acute myocardial infarction. Methods 224 elderly patients with acute myocardial infarction were randomly divided into control group and observation group, 112 cases each. Patients in the control group were treated with thrombolytic therapy. Patients in the observation group were treated with percutaneous coronary intervention, and the clinical effects were compared between the two groups. Results After treatment, 43 cases were effective in the control group, 47 cases were effective, 22 cases were ineffective; 63 cases were effective in the observation group, 42 cases were effective and 7 cases were ineffective; The total effective rate in the control group was 80.4%, which was lower than that in the observation group 93.8%, the difference was statistically significant (P <0.05). During the treatment, the incidence of adverse reactions in the observation group was 6.3%, including 1 case of allergy, 3 cases of bleeding and 3 cases of ventricular arrhythmia. The incidence of adverse reactions in the control group was 17.9%, including 5 cases of allergy, 6 cases of bleeding Cases, ventricular arrhythmia in 9 cases; observation group adverse reactions were lower than the control group, the difference was statistically significant (P <0.05). Conclusion In the treatment of elderly patients with acute myocardial infarction, the clinical effect of percutaneous coronary intervention is more significant than that of conventional intravenous thrombolytic therapy, and it can also reduce the adverse reaction during treatment, which has the promotion value.